medigraphic.com
ISSN 0035-0052 (Impreso)

2009, Número 5

<< Anterior

Rev Mex Pediatr 2009; 76 (5)


Surfactante pulmonar en el síndrome de dificultad respiratoria

Jiménez JJR, Castellanos RK

Idioma: Español
Referencias bibliográficas: 26
Paginas: 231-236
Archivo PDF: 79.28 Kb.


RESUMEN

El surfactante pulmonar exógeno es un fármaco fundamental en el tratamiento de neonatos con el síndrome de dificultad respiratoria; es por esta razón importante conocer los diferentes tipos disponibles en el mercado, sus antecedentes y las propiedades de éstos, así como informar las dosis, los componentes farmacológicos y las indicaciones de los tipos de surfactante pulmonar que existen en el mercado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Villanueva GD, Fernández MP, Hernáiz AM. Desarrollo del sistema pulmonar y surfactante. En: Insuficiencia respiratoria neonatal, PAC neonatología 1 libro 3 Intersistemas; 2003: 143-4.

  2. Jasso GL, Vargas OA, Villegas SR. Síndrome de dificultad respiratoria. En: Arellano PM, editores. Cuidados intensivos en pediatría. 3a edición. México: Interamericana McGraw-Hill; 1994: 206-19.

  3. Salinas RV, Zapata PJ. Surfactante pulmonar. En: Rodríguez WM, Udaeta ME editores. Neonatología clínica. México: McGraw-Hill 2004: 265-74.

  4. Sinha S, Moya F, Donn S. Surfactant for respiratory distress syndrome: are there important clinical differences among preparation? Curr Opin Pediatr 2007; 19: 150-4.

  5. Craig LM, Sean BA. An update on the use of surfactant in neonates. Current Pediatrics 2004; 14: 284-9.

  6. Lyra PP, Diniz EM. The importance of surfactant on the development of neonatal pulmonary diseases. Clinics (Sao Paulo) 2007; 62(2): 181-90.

  7. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1(8159): 55-9.

  8. Engle WA. American Academy of Pediatrics committee on fetus and newborn. Surfactant replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121(2): 419-32.

  9. Jobe AH. Pharmacology review: Why surfactant works for respiratory distress syndrome. Neo Reviews 2006; 7: e95-e106.

  10. Kattwinkel J. Surfactant. Evolving issues. Clin Perinatol 1998; 25: 17-32.

  11. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; (2): CD 000511.

  12. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; (2): CD 001079.

  13. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; (2): CD 000510.

  14. Gortner L, Wauer RR, Hammer H, Stock GJ, Heitmann F, Reiter HL et al. Early versus late surfactant treatment in preterm infants of 27 to 32 weeks gestational age: A multicenter controlled clinical trial. Pediatrics 1998; 102(5): 1153-60.

  15. Tooley WH, Clements JA, Muramatsu K, Brown CL, Schlueter MA. Lung function in prematurely delivered rabbits treated with a synthetic surfactant. Am Rev Respir Dis 1987; 136(3): 651-6.

  16. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group. Pediatrics 1988; 82(5): 683-91.

  17. Bhutani VK, Abbasi S, Long WA, Gerdes JS. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant. J Pediatr 1992; 120(2 Pt 2): S18-24.

  18. Billman D, Nicks J, Schumacher R. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome. Pediatr Pulmonol 1994; 18(5): 279-83.

  19. Hamdan AH, Shaw NJ. Changes in pulmonary artery pressure during the acute phase of respiratory distress syndrome treated with three different types of surfactant. Pediatr Pulmonol 1998; 25(3): 191-5.

  20. Kääpä P, Seppänen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr 1993; 123(1): 115-9.

  21. Skinner J. The effects of surfactant on haemodynamics in hyaline membrane disease. Arch Dis Child Fetal Neonatal Ed. 1997; 76(2): F67-9.

  22. Bihar Pedicon 2006 Bihar: Conference Abstract on Pediatric Oncall. Available from: http://www.pediatriconcall.com

  23. Sinha SK, Lacaze-Masmonteil T, Valls I, Soler A, Wiswell TE, Gadzinowski J, Hajdu J et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115(4): 1030-8.

  24. Blanco HO. Propiedades antiinflamatorias del surfactante pulmonar y su aplicación en la clínica. Biotecnología Aplicada 2004; 21: 70-76.

  25. Young TE, Mangum B. Surfactantes en Neo Fax Ver 9.0.8/2006.11.9 Skyscape palm software.

  26. Moya F, Sinha S, Gadzinowski J, D’Agostino R, Segal R, Guardia C et al. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 2007; 119(6): e1361-70.




2020     |     www.medigraphic.com